TY - JOUR
T1 - Antiepileptic medications in autism spectrum disorder
T2 - A systematic review and meta-analysis
AU - Hirota, Tomoya
AU - Veenstra-Vanderweele, Jeremy
AU - Hollander, Eric
AU - Kishi, Taro
N1 - Funding Information:
Acknowledgments Dr. Kishi has received speaker’s honoraria from Abbott, Astellas, Daiichi Sankyo, Dainippon Sumitomo, Eli Lilly, GlaxoSmithKline, Yoshitomi, Otsuka, Meiji, Shionogi, Tanabe-Mitsubishi, Novartis and Pfizer. Dr. Veenstra-VanderWeele has received research funding from Seaside Therapeutics, Novartis, Roche, Forest, and SynapDx. He has served on an advisory board for Novartis. Dr. Hollander has received research funding from Abbott, UCB Pharma, Roche, Forest. He has served on advisory boards for Abbott, Roche, Neuropharm and Coronado. Dr. Hirota has nothing to disclose.
PY - 2014/4
Y1 - 2014/4
N2 - Electroencephalogram-recorded epileptiform activity is common in children with autism spectrum disorder (ASD), even without clinical seizures. A systematic literature search identified 7 randomized, placebo-controlled trials of antiepileptic drugs (AEDs) in ASD (total n = 171), including three of valproate, and one each of lamotrigine, levetiracetam, and topiramate. Meta-analysis revealed no significant difference between medication and placebo in four studies targeting irritability/agitation and three studies investigating global improvement, although limitations include lack of power and different medications with diverse actions. Across all seven studies, there was no significant difference in discontinuation rate between two groups. AEDs do not appear to have a large effect size to treat behavioral symptoms in ASD, but further research is needed, particularly in the subgroup of patients with epileptiform abnormalities.
AB - Electroencephalogram-recorded epileptiform activity is common in children with autism spectrum disorder (ASD), even without clinical seizures. A systematic literature search identified 7 randomized, placebo-controlled trials of antiepileptic drugs (AEDs) in ASD (total n = 171), including three of valproate, and one each of lamotrigine, levetiracetam, and topiramate. Meta-analysis revealed no significant difference between medication and placebo in four studies targeting irritability/agitation and three studies investigating global improvement, although limitations include lack of power and different medications with diverse actions. Across all seven studies, there was no significant difference in discontinuation rate between two groups. AEDs do not appear to have a large effect size to treat behavioral symptoms in ASD, but further research is needed, particularly in the subgroup of patients with epileptiform abnormalities.
KW - Anticonvulsant
KW - Antiepileptic
KW - Autism
KW - Mood stabilizer
KW - Pervasive developmental disorder
UR - http://www.scopus.com/inward/record.url?scp=84893273545&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84893273545&partnerID=8YFLogxK
U2 - 10.1007/s10803-013-1952-2
DO - 10.1007/s10803-013-1952-2
M3 - Review article
C2 - 24077782
AN - SCOPUS:84893273545
SN - 0162-3257
VL - 44
SP - 948
EP - 957
JO - Journal of Autism and Developmental Disorders
JF - Journal of Autism and Developmental Disorders
IS - 4
ER -